Intellia Therapeutics Inc(NTLA)stock report

Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company’s sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company’s division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company’s subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.

Current cash: 271M, Latest quarter loss: 26M,可以烧2.5年。

Date Cash % last year % last quarter
 2018.9.30 293M 31.98% -4.25%
2018.12.31 314M -7.92% 7.17%
 2019.3.31 297M -9.45% -5.41%
2019.6.31 271M -11.44% -8.75%


Date Profit % last year % last quarter
 2018.9.30 -66.28M -52.08% -52.09%
2018.12.31 -85.34M -26.35% -28.76%
 2019.3.31 -21.94M -2.73% 74.29%
2019.6.31 -47.62M -9.29% -117.05%


Insider Transactions:

Institution Ownership:


Analyst Ratings:

Leave a Reply